Hypofractionated Intensity-Modulated Arc Therapy for Lymph Node Metastasized Prostate Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 4, 2009, Pages 1013-1020

  Fonteyne, Valérie ^a   De Gersem, Werner ^a   De Neve, Wilfried ^a   Jacobs, Filip ^a   Lumen, Nicolaas ^a   Vandecasteele, Katrien ^a   Villeirs, Geert ^a   De Meerleer, Gert ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Acute toxicity; Hypofractionation; IMAT; Intensity modulated arc therapy; N1 prostate cancer

Indexed keywords

ACUTE TOXICITY; ANDROGEN DEPRIVATION; CLINICAL TARGET VOLUMES; DIMENSIONAL EXPANSION; GASTROINTESTINAL TOXICITIES; GENITOURINARY TOXICITIES; HYPOFRACTIONATION; INTENSITY-MODULATED ARC THERAPIES; INTESTINAL TOXICITY; LATE EFFECTS; LOW TOXICITY; LYMPH NODE; NORMAL TISSUE; PLANNING TARGET VOLUMES; PRIMARY TREATMENT; PROSTATE CANCERS; RADIATION THERAPY ONCOLOGY GROUPS; SCORING SYSTEMS; SEMINAL VESICLE; UP TIME;

BODY FLUIDS; CAVITY RESONATORS; FLUORINE CONTAINING POLYMERS; ONCOLOGY; PHYSICAL THERAPY; RADIATION EFFECTS; THREE DIMENSIONAL; TOXICITY; TUMORS;

RADIOTHERAPY;

CYPROTERONE ACETATE; GONADORELIN DERIVATIVE; ANTIANDROGEN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ACUTE TOXICITY; ADULT; AGED; ANAL PAIN; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSIMETRY; DYSURIA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMATEMESIS; HEMATURIA; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MALE; MUSCLE CRAMP; NAUSEA; NOCTURIA; POLLAKISURIA; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SCORING SYSTEM; SEMINAL VESICLE; TREATMENT PLANNING; URINARY FREQUENCY; URINARY URGENCY; UROGENITAL TRACT TOXICITY; COMPUTER ASSISTED RADIOTHERAPY; LARGE INTESTINE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RADIATION EXPOSURE; SMALL INTESTINE; TUMOR VOLUME; UROGENITAL SYSTEM;

AGED; ANDROGEN ANTAGONISTS; DOSE FRACTIONATION; FOLLOW-UP STUDIES; HUMANS; INTESTINE, LARGE; INTESTINE, SMALL; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; SEMINAL VESICLES; TUMOR BURDEN; UROGENITAL SYSTEM;

EID: 70449721428     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.12.047     Document Type: Article

References (54)

1. Cooperberg M.R., Lubeck D.P., Mehta S.S., et al. CaPSURE: Time trends in clinical risk stratification for prostate cancer: Implications for outcomes (data from CaPSURE). J Urol 170 (2003) S21-S27 (erratum: J Urol (2004;171:811)
2. Cooperberg M.R., Moul J.W., and Carroll P.R. The changing face of prostate cancer. J Clin Oncol 23 (2005) 8146-8151
3. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs. high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239
4. Peeters S.T., Heemsbergen W.D., Koper P.C., et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
5. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53 (2002) 1111-1116
6. Pollack A., Hanlon A., Horwitz E., et al. Prostate cancer radiotherapy dose response: An update of the Fox Chase experience. J Urol 171 (2004) 1132-1136
7. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RTO1 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
8. Kao J., Stone N.N., Lavaf A., et al. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Int J Radiat Oncol Biol Phys 70 (2008) 96-101
9. Pavlovich C.P., Trock B.J., Sulman A., et al. 3-Year actuarial biochemical recurrence-free survival following laparoscopic radical prostatectomy: Experience from a tertiary referral center in the United States. J Urol 179 (2008) 917-921
10. Zagars G.K., Pollack A., von Eschenbach A.C., et al. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 80 (1997) 764-775
11. Lawton C.A., Cox J.D., Glisch C., et al. Is long-term survival with external beam irradiation for stage D1 adenocarcinoma of the prostate?. Cancer 69 (1992) 2671-2676
12. Kupelian P.A., Katcher J., Levin H.S., et al. Stage T1-T2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37 (1997) 1043-1052
13. Colleen A., Winter K., Byhardt R., et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 38 (1997) 931-939
14. Whittington R., Malkowicz S., Machtay M., et al. The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer. Int J Radiat Oncol Biol Phys 39 (1997) 673-680
15. Robnett T., Whittington R., Malkowicz S., et al. Long-term use of combined radiation therapy and hormonal therapy in the management of stage D1 prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 1146-1151
16. Pollack A., Zagars G., Antolak J., et al. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54 (2002) 677-685
17. Jacob R., Hanlon A., Horwitz E., et al. The relationship of increasing radiotherapy dose to reduced distant metastasis and mortality in men with prostate cancer. Cancer 100 (2004) 538-543
18. Pollack A., Smith L.G., and von Eschenbach A.C. External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48 (2000) 507-512
19. Coen J.J., Zietman A.L., Thakral H., et al. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20 (2002) 3199-3205
20. Ashman J.B., Zelefsky M.J., Hunt M.S., et al. Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 63 (2005) 765-771
21. Cozzarini C., Fiorino C., Muzio N.D., et al. Significant reduction of acute toxicity following pelvic irradiation with helical tomotherapy in patients with localized prostate cancer. Radiother Oncol 84 (2007) 164-170
22. De Meerleer G.O., Fonteyne V.H., Vakaet L., et al. Intensity-modulated radiation therapy for prostate cancer: Late morbidity and results on biochemical control. Radiother Oncol 82 (2007) 160-166
23. De Meerleer G.O., Vakaet L.A., De Gersem W.R., et al. Radiotherapy of prostate cancer with or without intensity modulated beams: A planning comparison. Int J Radiat Oncol Biol Phys 47 (2000) 639-648
24. Duthoy W., De Gersem W., Vergote K., et al. Clinical implementation of intensity-modulated arc therapy (IMAT) for rectal cancer. Int J Radiat Oncol Biol Phys 60 (2004) 794-806
25. King C.R., and Fowler J.F. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys 51 (2001) 213-214
26. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumours show high sensitivity to fractionation (low alpha/beta ratio), similar to late responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
27. Wang J.Z., Guerrero M., and Li X.A. How low is the α/β ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 55 (2003) 194-203
28. Kal H.B., and Van Gellekom M.P.R. How low is the α/β ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 57 (2003) 1116-1121
29. Kupelian P.A., Willoughby T.R., Reddy C.A., et al. Hypofractionation intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 68 (2007) 1424-1430
30. Arcangeli S., Saracino B., Petrongari M.G., et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 84 (2007) 148-155
31. Yeoh E.E., Holloway R.H., Fraser R.J., et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: Updated results of a phase III randomized trial. Int J Radiat Oncol Biol Phys 66 (2006) 1072-1083
32. Pollack A., Hanlon A.L., Horwitz A.M., et al. Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial. Int J Radiat Oncol Biol Phys 64 (2006) 518-5126
33. Fonteyne V., Villeirs G., Speleers B., et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with a simultaneous integrated boost on the intraprostatic lesion. Int J Radiat Oncol Biol Phys 72 (2008) 777-781
34. Roach III M., Marquez C., Yuo H.S., et al. Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 28 (1994) 33-37
35. American Joint Committee on Cancer. Manual for staging of cancer. 5th ed. (1997), JB Lippincott, Philadelphia
36. De Meerleer G., Villeirs G., Bral S., et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: Planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 75 (2005) 325-333
37. De Meerleer G., Vakaet L., Meersschout S., et al. Intensity-modulated radiotherapy as primary therapy for prostate cancer: Acute toxicity in 114 patients. Int J Radiat Oncol Biol Phys 60 (2004) 777-787
38. Fonteyne V., De Neve W., Villeirs G., et al. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: The need for adapting toxicity scales. Radiother Oncol 84 (2007) 156-163
39. Raghavaiah N.V., and Jordan Jr. W.P. Prostatic lymphography. J Urol 121 (1979) 178-181
40. Cerny J.C., Farah R., Rian R., et al. An evaluation of lymphangiography in staging carcinoma of prostate. J Urol 113 (1975) 367-370
41. Brossner C., Ringhofer H., Hernady T., et al. Lymphatic drainage of prostatic transition and peripheral zones visualized on a three-dimensional workstation. Urology 57 (2001) 389-393
42. Duthoy W., De Gersem W., Vergote K., et al. Whole abdominopelvic radiotherapy (WAPRT) using intensity modulated arc therapy (IMAT): First clinical experience. Int J Radiat Oncol Biol Phys 58 (2003) 1019-1032
43. De Meerleer G., Vakaet L., De Gersem W., et al. Direct segmentation aperture and weight optimization for intensity-modulated radiotherapy of prostate cancer. Strahlenther Oncol 180 (2004) 136-143
44. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
45. Lawton C.A., Winter K., Byhardt R., et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Int J Radiat Oncol Biol Phys 38 (1997) 931-939
46. Wang-Chesebro X.P., Coleman Y., et al. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 66 (2006) 654-662
47. Sanguineti G., Cavey M.L., Endres E., et al. Does treatment of the pelvic nodes with IMRT increase late rectal toxicity over conformal prostate-only radiotherapy to 76 Gy?. Strahlenther Onkol 182 (2006) 543-549
48. Yuen J., Rodrigues G., Trenka K., et al. Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer. Radiother Oncol Epub (2008 Jan 7). doi: 10.1186/1748-717X-3-1
49. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): Multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 47 (2000) 103-113
50. Kupelian A.P., Reddy C.A., Carlson T.P., et al. Preliminary observations on biochemical relapse-free survival after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer. Int J Radiat Oncol Biol Phys 53 (2002) 904-912
51. Liu L., Glicksman A.S., Coachman N., et al. Low acute gastrointestinal and genitourinary toxicities in whole pelvic irradiation of prostate cancer. Int J Radiat Oncol Biol Phys 38 (1997) 65-71
52. Koper P.C., Jansen P., Van Putten W., et al. Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: Observations of a randomized trial. Int J Radiat Oncol 73 (2004) 1-9
53. Pommier P., Chabaud S., Lagrange J.L., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 34 (2007) 5366-5373
54. Muren L.P., Wasbo E., Helle S.I., et al. Intensity-modulated radiotherapy of pelvic lymph nodes in locally advanced prostate cancer: planning procedures and early experiences. Int J Radiat Oncol 71 (2008) 1034-1041